Market Overview

Shares of Synta Moving Higher Following News of Fast Track Designation for Ganetespib

Related SNTA
InterMune's Roche Deal Sends Peer Group Up
Synta Announces Advancement Of Ganetespib Into Phase 3 Extension Of AML LI-1 Study For Patients With AML And High-Risk MDS

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of ganetespib, the Company's lead Hsp90 inhibitor drug candidate, to improve overall survival when administered in combination with docetaxel for the treatment of patients with metastatic non-small cell lung adenocarcinoma who have progressed following one prior chemotherapy regimen. FDA's Fast Track Drug Development Program is designed to facilitate the clinical development and expedite the review of drugs that are intended to treat serious medical conditions and that demonstrate the potential to fill unmet medical needs.

Posted-In: News FDA

 

Related Articles (SNTA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters